These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

68 related items for PubMed ID: 11751484

  • 1. PNU-145156E, a novel angiogenesis inhibitor, in patients with solid tumors: a phase I and pharmacokinetic study.
    Groen HJ, de Vries EG, Wynendaele W, van der Graaf WT, Fokkema E, Lechuga MJ, Poggesi I, Dirix LY, van Oosterom AT.
    Clin Cancer Res; 2001 Dec; 7(12):3928-33. PubMed ID: 11751484
    [Abstract] [Full Text] [Related]

  • 2. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
    Supko JG, Eder JP, Ryan DP, Seiden MV, Lynch TJ, Amrein PC, Kufe DW, Clark JW.
    Clin Cancer Res; 2003 Nov 01; 9(14):5178-86. PubMed ID: 14613997
    [Abstract] [Full Text] [Related]

  • 3. Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, which was administered to patients with advanced solid tumors on days 1 and 8 in 3-week courses.
    Tamura K, Nakagawa K, Kurata T, Satoh T, Nogami T, Takeda K, Mitsuoka S, Yoshimura N, Kudoh S, Negoro S, Fukuoka M.
    Cancer Chemother Pharmacol; 2007 Jul 01; 60(2):285-93. PubMed ID: 17136542
    [Abstract] [Full Text] [Related]

  • 4. A phase I and pharmacokinetic study of tallimustine [PNU 152241 (FCE 24517)] in patients with advanced cancer.
    Weiss GR, Poggesi I, Rocchetti M, DeMaria D, Mooneyham T, Reilly D, Vitek LV, Whaley F, Patricia E, Von Hoff DD, O'Dwyer P.
    Clin Cancer Res; 1998 Jan 01; 4(1):53-9. PubMed ID: 9516952
    [Abstract] [Full Text] [Related]

  • 5. Phase I and pharmacokinetic study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously on days 1, 3, and 5 every 3 weeks in patients with advanced solid tumors.
    Cunningham C, Appleman LJ, Kirvan-Visovatti M, Ryan DP, Regan E, Vukelja S, Bonate PL, Ruvuna F, Fram RJ, Jekunen A, Weitman S, Hammond LA, Eder JP.
    Clin Cancer Res; 2005 Nov 01; 11(21):7825-33. PubMed ID: 16278405
    [Abstract] [Full Text] [Related]

  • 6. A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia.
    Gimsing P, Hansen M, Knudsen LM, Knoblauch P, Christensen IJ, Ooi CE, Buhl-Jensen P.
    Eur J Haematol; 2008 Sep 01; 81(3):170-6. PubMed ID: 18510700
    [Abstract] [Full Text] [Related]

  • 7. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
    Murren J, Modiano M, Clairmont C, Lambert P, Savaraj N, Doyle T, Sznol M.
    Clin Cancer Res; 2003 Sep 15; 9(11):4092-100. PubMed ID: 14519631
    [Abstract] [Full Text] [Related]

  • 8. A Phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with solid tumors.
    Rademaker-Lakhai JM, Terret C, Howell SB, Baud CM, De Boer RF, Pluim D, Beijnen JH, Schellens JH, Droz JP.
    Clin Cancer Res; 2004 May 15; 10(10):3386-95. PubMed ID: 15161693
    [Abstract] [Full Text] [Related]

  • 9. Phase 1 study of weekly polyethylene glycol-camptothecin in patients with advanced solid tumors and lymphomas.
    Posey JA, Saif MW, Carlisle R, Goetz A, Rizzo J, Stevenson S, Rudoltz MS, Kwiatek J, Simmons P, Rowinsky EK, Takimoto CH, Tolcher AW.
    Clin Cancer Res; 2005 Nov 01; 11(21):7866-71. PubMed ID: 16278410
    [Abstract] [Full Text] [Related]

  • 10. A phase I study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously daily for 5 consecutive days every 3 weeks in patients with advanced solid tumors.
    Ebbinghaus S, Rubin E, Hersh E, Cranmer LD, Bonate PL, Fram RJ, Jekunen A, Weitman S, Hammond LA.
    Clin Cancer Res; 2005 Nov 01; 11(21):7807-16. PubMed ID: 16278403
    [Abstract] [Full Text] [Related]

  • 11. Phase I and pharmacokinetic study of E7070, a chloroindolyl-sulfonamide anticancer agent, administered on a weekly schedule to patients with solid tumors.
    Dittrich C, Dumez H, Calvert H, Hanauske A, Faber M, Wanders J, Yule M, Ravic M, Fumoleau P.
    Clin Cancer Res; 2003 Nov 01; 9(14):5195-204. PubMed ID: 14613999
    [Abstract] [Full Text] [Related]

  • 12. Phase I trial of oral MAC-321 in subjects with advanced malignant solid tumors.
    Lockhart AC, Bukowski R, Rothenberg ML, Wang KK, Cooper W, Grover J, Appleman L, Mayer PR, Shapiro M, Zhu AX.
    Cancer Chemother Pharmacol; 2007 Jul 01; 60(2):203-9. PubMed ID: 17091249
    [Abstract] [Full Text] [Related]

  • 13. Phase I clinical and pharmacokinetic study of plitidepsin as a 1-hour weekly intravenous infusion in patients with advanced solid tumors.
    Izquierdo MA, Bowman A, García M, Jodrell D, Martinez M, Pardo B, Gómez J, López-Martin JA, Jimeno J, Germá JR, Smyth JF.
    Clin Cancer Res; 2008 May 15; 14(10):3105-12. PubMed ID: 18483378
    [Abstract] [Full Text] [Related]

  • 14. Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors.
    Eskens FA, Steeghs N, Verweij J, Bloem JL, Christensen O, van Doorn L, Ouwerkerk J, de Jonge MJ, Nortier JW, Kraetzschmar J, Rajagopalan P, Gelderblom H.
    J Clin Oncol; 2009 Sep 01; 27(25):4169-76. PubMed ID: 19636022
    [Abstract] [Full Text] [Related]

  • 15. A prolonged methoxymorpholino doxorubicin (PNU-152243 or MMRDX) infusion schedule in patients with solid tumours: a phase 1 and pharmacokinetic study.
    Fokkema E, Verweij J, van Oosterom AT, Uges DR, Spinelli R, Valota O, de Vries EG, Groen HJ.
    Br J Cancer; 2000 Feb 01; 82(4):767-71. PubMed ID: 10732743
    [Abstract] [Full Text] [Related]

  • 16. A Phase I study of bizelesin (NSC 615291) in patients with advanced solid tumors.
    Pitot HC, Reid JM, Sloan JA, Ames MM, Adjei AA, Rubin J, Bagniewski PG, Atherton P, Rayson D, Goldberg RM, Erlichman C.
    Clin Cancer Res; 2002 Mar 01; 8(3):712-7. PubMed ID: 11895900
    [Abstract] [Full Text] [Related]

  • 17. A phase I and pharmacokinetic study of SAM486A, a novel polyamine biosynthesis inhibitor, administered on a daily-times-five every-three-week schedule in patients with Advanced solid malignancies.
    Siu LL, Rowinsky EK, Hammond LA, Weiss GR, Hidalgo M, Clark GM, Moczygemba J, Choi L, Linnartz R, Barbet NC, Sklenar IT, Capdeville R, Gan G, Porter CW, Von Hoff DD, Eckhardt SG.
    Clin Cancer Res; 2002 Jul 01; 8(7):2157-66. PubMed ID: 12114416
    [Abstract] [Full Text] [Related]

  • 18. A phase I and pharmacokinetic study of LAF389 administered to patients with advanced cancer.
    Dumez H, Gall H, Capdeville R, Dutreix C, van Oosterom AT, Giaccone G.
    Anticancer Drugs; 2007 Feb 01; 18(2):219-25. PubMed ID: 17159608
    [Abstract] [Full Text] [Related]

  • 19. Phase I study of ONO-4007, a synthetic analogue of the lipid A moiety of bacterial lipopolysaccharide.
    de Bono JS, Dalgleish AG, Carmichael J, Diffley J, Lofts FJ, Fyffe D, Ellard S, Gordon RJ, Brindley CJ, Evans TR.
    Clin Cancer Res; 2000 Feb 01; 6(2):397-405. PubMed ID: 10690516
    [Abstract] [Full Text] [Related]

  • 20. A phase I, first in man study of OSI-7836 in patients with advanced refractory solid tumors: IND.147, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group.
    Goss G, Siu LL, Gauthier I, Chen EX, Oza AM, Goel R, Maroun J, Powers J, Walsh W, Maclean M, Drolet DW, Rusk J, Seymour LK, Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group.
    Cancer Chemother Pharmacol; 2006 Nov 01; 58(5):703-10. PubMed ID: 16528532
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.